Relay Therapeutics, Inc.

Equities

RLAY

US75943R1023

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:08 2024-05-17 EDT			5-day change	1st Jan Change
6.625 ^USD	+1.77%		+3.19%	-39.83%

05-14	Transcript : Relay Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM
05-10	Barclays Upgrades Relay Therapeutics to Overweight From Equalweight With $15 Price Target	MT

Relay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 02, 2024 at 04:16 pm

Relay Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 10.01 million compared to USD 0.226 million a year ago. Net loss was USD 81.39 million compared to USD 94.24 million a year ago.

Basic loss per share from continuing operations was USD 0.62 compared to USD 0.78 a year ago.

Latest news about Relay Therapeutics, Inc.

Transcript : Relay Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM	05-14
Barclays Upgrades Relay Therapeutics to Overweight From Equalweight With $15 Price Target	05-10	MT
Oppenheimer Adjusts Relay Therapeutics Price Target to $25 From $33, Maintains Outperform Rating	05-06	MT
Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q1 Revenue $10M	05-02	MT
Relay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Transcript : Relay Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM	03-12
Relay Therapeutics Q4 Loss Widens, Reports No Revenue	02-23	MT
Relay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Relay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Relay Therapeutics, Inc. announced that it has received $30 million in funding	01-09	CI
Transcript : Relay Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 02:15 PM	01-09
Relay Therapeutics to Raise $30 Million From Private Placement	01-08	MT
Relay Therapeutics, Inc. announced that it expects to receive $30 million in funding	01-07	CI
HC Wainwright Adjusts Price Target on Relay Therapeutics to $17 From $19, Keeps Buy Rating	12-11	MT
HC Wainwright Lowers Price Target on Relay Therapeutics to $19 From $33, Maintains Buy Rating	11-08	MT
Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q3 Revenue $25.2M	11-02	MT
Relay Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Transcript : Relay Therapeutics, Inc. - Special Call	23-10-12
Relay Therapeutics' Cancer Medicine Benefits Patients, Initial Data Shows; Shares Jump	23-10-12	MT
Relay Therapeutics, Inc. Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors	23-10-12	CI
HC Wainwright Adjusts Price Target on Relay Therapeutics to $30 From $32, Keeps Buy Rating	23-08-17	MT
Relay Therapeutics' Q2 Loss Widens	23-08-09	MT
Relay Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q2 Revenue $119,000	23-08-08	MT
Relay Therapeutics, Inc.(NasdaqGM:RLAY) dropped from Russell 3000E Growth Index	23-06-23	CI

Chart Relay Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Companyâs Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Companyâs lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3KÎ±), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-06-03 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Relay Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.625 USD

Average target price

21.96 USD

Spread / Average Target

+231.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RELAY THERAPEUTICS, INC.	-39.83%	864M
MODERNA, INC.	+33.63%	50.85B
IQVIA HOLDINGS INC.	-0.09%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	19.13B
BIO-TECHNE CORPORATION	+8.61%	13.05B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.08B

Other Biotechnology & Medical Research